Serum Institute looks to supply 25 million doses to Covax till December

Pune-based Serum Institute of India (SII) is expected to supply 25 million doses to the Covax facility till December, as it looks to resume supplies to the WHO-led Covax facility this month. Earlier in March, the government had imposed a hold on all major exports affecting the Covax deliveries.

“The supplies will resume soon. SII is supposed to supply 25 million doses till December,” a senior government official told ET.

In an interview to ET in October, SII CEO Adar Poonawalla said small exports will start soon. “I think January onwards there will be large exports to Covax because by then India will have more than enough vaccines. Already, there is more stock than what we are vaccinating. So, we will be in a very good situation. Combine that with the fact that other Indian vaccine manufacturers are also scaling up,” he told ET.

The Covax facility was created last year to ensure Covid vaccines were made available around the world, with richer countries subsidising costs for poorer nations. The scheme hoped to distribute enough vaccines to protect at least 20% of the population in 92 low-or medium-income countries.

  • Related Posts

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India